Page last updated: 2024-11-12

pyrrophenone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyrrophenone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11251471
CHEMBL ID221504
SCHEMBL ID2729840
MeSH IDM0426271

Synonyms (10)

Synonym
CHEMBL221504 ,
n-(((2s,4r)-1-(2-(2,4-difluorobenzoyl)benzoyl)-4-(tritylthio)pyrrolidin-2-yl)methyl)-4-((z)-(2,4-dioxothiazolidin-5-ylidene)methyl)benzamide
bdbm50205527
pyrrophenone
341973-06-6
SCHEMBL2729840
n-[[(2s,4r)-1-[2-(2,4-difluorobenzoyl)benzoyl]-4-tritylsulfanylpyrrolidin-2-yl]methyl]-4-[(z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]benzamide
MS-31573
HY-111376
AKOS040755762

Research Excerpts

Overview

Pyrrophenone is a more potent and specific cPLA2alpha inhibitor than MAFP and AACOCF3. It represents an excellent pharmacological tool to investigate the biosynthesis and the biological roles of eicosanoids and PAF.

ExcerptReferenceRelevance
"Pyrrophenone is a more potent and specific cPLA2alpha inhibitor than MAFP and AACOCF3 and represents an excellent pharmacological tool to investigate the biosynthesis and the biological roles of eicosanoids and PAF."( Effects of pyrrophenone, an inhibitor of group IVA phospholipase A2, on eicosanoid and PAF biosynthesis in human neutrophils.
Borgeat, P; Bourgoin, SG; Flamand, N; Lemieux, L; Picard, S; Pouliot, M, 2006
)
2.17

Treatment

ExcerptReferenceRelevance
"Treatment with pyrrophenone (a selective inhibitor of cPLA(2)alpha) completely inhibited the TNFalpha-induced release of AA, but only partially inhibited the TNFalpha/zVAD-induced response in L929 cells."( Release of arachidonic acid induced by tumor necrosis factor-alpha in the presence of caspase inhibition: evidence for a cytosolic phospholipase A2alpha-independent pathway.
Azuma, C; Enomoto, M; Hirabayashi, T; Kaneko, M; Kurosawa, T; Matsumoto, Y; Murayama, T; Nakamura, H; Okuma, Y; Shimizu, M, 2008
)
0.69

Dosage Studied

ExcerptRelevanceReference
" The results implicate a serine hydrolase in regulating ER calcium release and highlight the importance of careful dose-response studies with pyrrophenone to study cPLA2α function."( Off-target effect of the cPLA2α inhibitor pyrrophenone: Inhibition of calcium release from the endoplasmic reticulum.
Ewing, H; Gelb, MH; Lee, H; Leslie, CC; Yun, B, 2016
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytosolic phospholipase A2Homo sapiens (human)IC50 (µMol)0.11000.00051.09862.3000AID280304
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processCytosolic phospholipase A2Homo sapiens (human)
positive regulation of T-helper 1 type immune responseCytosolic phospholipase A2Homo sapiens (human)
glycerol metabolic processCytosolic phospholipase A2Homo sapiens (human)
monoacylglycerol biosynthetic processCytosolic phospholipase A2Homo sapiens (human)
platelet activating factor biosynthetic processCytosolic phospholipase A2Homo sapiens (human)
icosanoid metabolic processCytosolic phospholipase A2Homo sapiens (human)
positive regulation of platelet activationCytosolic phospholipase A2Homo sapiens (human)
arachidonic acid metabolic processCytosolic phospholipase A2Homo sapiens (human)
leukotriene biosynthetic processCytosolic phospholipase A2Homo sapiens (human)
positive regulation of prostaglandin secretionCytosolic phospholipase A2Homo sapiens (human)
phosphatidylglycerol catabolic processCytosolic phospholipase A2Homo sapiens (human)
phosphatidylcholine catabolic processCytosolic phospholipase A2Homo sapiens (human)
phosphatidylcholine acyl-chain remodelingCytosolic phospholipase A2Homo sapiens (human)
regulation of cell population proliferationCytosolic phospholipase A2Homo sapiens (human)
positive regulation of macrophage activationCytosolic phospholipase A2Homo sapiens (human)
arachidonic acid secretionCytosolic phospholipase A2Homo sapiens (human)
establishment of localization in cellCytosolic phospholipase A2Homo sapiens (human)
cellular response to antibioticCytosolic phospholipase A2Homo sapiens (human)
glycerophospholipid catabolic processCytosolic phospholipase A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
lysophospholipase activityCytosolic phospholipase A2Homo sapiens (human)
phospholipase A2 activityCytosolic phospholipase A2Homo sapiens (human)
calcium ion bindingCytosolic phospholipase A2Homo sapiens (human)
calcium-dependent phospholipid bindingCytosolic phospholipase A2Homo sapiens (human)
O-acyltransferase activityCytosolic phospholipase A2Homo sapiens (human)
phosphatidylinositol-5-phosphate bindingCytosolic phospholipase A2Homo sapiens (human)
phosphatidylinositol-3-phosphate bindingCytosolic phospholipase A2Homo sapiens (human)
calcium-dependent phospholipase A2 activityCytosolic phospholipase A2Homo sapiens (human)
calcium-independent phospholipase A2 activityCytosolic phospholipase A2Homo sapiens (human)
phosphatidylinositol-4-phosphate bindingCytosolic phospholipase A2Homo sapiens (human)
phosphatidyl phospholipase B activityCytosolic phospholipase A2Homo sapiens (human)
ceramide 1-phosphate bindingCytosolic phospholipase A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
Golgi membraneCytosolic phospholipase A2Homo sapiens (human)
nuclear envelopeCytosolic phospholipase A2Homo sapiens (human)
cytoplasmCytosolic phospholipase A2Homo sapiens (human)
mitochondrial inner membraneCytosolic phospholipase A2Homo sapiens (human)
endoplasmic reticulum membraneCytosolic phospholipase A2Homo sapiens (human)
cytosolCytosolic phospholipase A2Homo sapiens (human)
intracellular membrane-bounded organelleCytosolic phospholipase A2Homo sapiens (human)
nucleusCytosolic phospholipase A2Homo sapiens (human)
endoplasmic reticulumCytosolic phospholipase A2Homo sapiens (human)
Golgi apparatusCytosolic phospholipase A2Homo sapiens (human)
cytosolCytosolic phospholipase A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID280304Inhibition of human cPLA2 alpha by GLU micelle assay2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha.
AID1187020Antiinflammatory activity against C3H/HeN mouse abdominal cavity cells assessed as inhibition of LPS-induced PGE2 production after 6 hrs by EIA2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Design, synthesis, and biological evaluation of 3-(1-Aryl-1H-indol-5-yl)propanoic acids as new indole-based cytosolic phospholipase A2α inhibitors.
AID280307Inhibition of A-23187-stimulated TXB2 production in Sprague-Dawley rat whole blood2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (59.09)29.6817
2010's9 (40.91)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.88 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]